| Revision as of 00:08, 13 January 2012 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated '') per Chem/Drugbox validation (report errors or bugs)← Previous edit | Revision as of 17:37, 2 April 2012 edit undo137.99.138.185 (talk)No edit summaryNext edit → | ||
| Line 52: | Line 52: | ||
| }} | }} | ||
| '''Troglitazone''' (Rezulin, Resulin or Romozin) is an ] and ] drug, and a member of the ] class of the ]s. It was developed by ](Japan). In the United States, it was introduced and manufactured by ] in the late 1990s, but turned out to be associated with an ] leading to drug-induced ]. One FDA medical officer evaluating troglitazone, John Gueriguian, did not recommend its approval due to potential high liver toxicity,<ref>, wired.com</ref> but a full panel of experts approved it in January 1997.<ref>{{cite journal | doi = 10.1007/s00125-006-0245-0 | title = Risks of troglitazone apparent before approval in USA | year = 2006 | last1 = Cohen | first1 = J. S. | journal = Diabetologia | volume = 49 | pages = 1454–5 | pmid = 16601971 | issue = 6}}</ref> Once the prevalence of adverse liver effects became known, troglitazone was withdrawn from the ] market in December 1997, from the ] market in 2000, and from the ] market soon afterwards. | '''Troglitazone''' (Rezulin, Resulin or Romozin) is an ] and ] drug, and a member of the ] class of the ]s. It was developed by ](Japan). In the United States, it was introduced and manufactured by ] in the late 1990s, but turned out to be associated with an ] leading to drug-induced ]. One FDA medical officer evaluating troglitazone, John Gueriguian, did not recommend its approval due to potential high liver toxicity,<ref>, wired.com</ref> but a full panel of experts approved it in January 1997.<ref>{{cite journal | doi = 10.1007/s00125-006-0245-0 | title = Risks of troglitazone apparent before approval in USA | year = 2006 | last1 = Cohen | first1 = J. S. | journal = Diabetologia | volume = 49 | pages = 1454–5 | pmid = 16601971 | issue = 6}}</ref> Once the prevalence of adverse liver effects became known, troglitazone was withdrawn from the ] market in December 1997, from the ] market in 2000, and from the ] market soon afterwards. | ||
| ==Mode of action== | ==Mode of action== | ||
Revision as of 17:37, 2 April 2012
Pharmaceutical compound | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 16-34 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H27NO5S |
| Molar mass | 441.541 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Troglitazone (Rezulin, Resulin or Romozin) is an anti-diabetic and antiinflammatory drug, and a member of the drug class of the thiazolidinediones. It was developed by Daiichi Sankyo Co.(Japan). In the United States, it was introduced and manufactured by Parke-Davis in the late 1990s, but turned out to be associated with an idiosyncratic reaction leading to drug-induced hepatitis. One FDA medical officer evaluating troglitazone, John Gueriguian, did not recommend its approval due to potential high liver toxicity, but a full panel of experts approved it in January 1997. Once the prevalence of adverse liver effects became known, troglitazone was withdrawn from the British market in December 1997, from the United States market in 2000, and from the Japanese market soon afterwards.
Mode of action
Troglitazone, like the other thiazolidinediones (pioglitazone and rosiglitazone), works by activating peroxisome proliferator-activated receptors (PPARs).
Troglitazone is a ligand to both PPARα and – more strongly – PPARγ. Troglitazone also contains an α-tocopheroyl moiety, potentially giving it vitamin E-like activity in addition to its PPAR activation. It has been shown to reduce inflammation: troglitazone use was associated with a decrease of nuclear factor kappa-B (NF-κB) and a concomitant increase in its inhibitor (IκB). NFκB is an important cellular transcription regulator for the immune response.
References
- Retired Drugs: Failed Blockbusters, Homicidal Tampering, Fatal Oversights, wired.com
- Cohen, J. S. (2006). "Risks of troglitazone apparent before approval in USA". Diabetologia. 49 (6): 1454–5. doi:10.1007/s00125-006-0245-0. PMID 16601971.
- Aljada A, Garg R, Ghanim H; et al. (2001). "Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?". J. Clin. Endocrinol. Metab. 86 (7): 3250–6. doi:10.1210/jc.86.7.3250. PMID 11443197.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)
External links
- Diabetes Monitor article on troglitazone
- RxList article on troglitazone